ArticleEuropean journal of cancer (Oxford, England : 1990)2022

TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.

Carl M Thielmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.